a b s t r a c t EP2 receptor has emerged as an important biological target for therapeutic intervention. In particular, it has been shown to exacerbate disease progression of a variety of CNS and peripheral diseases. Deletion of the EP2 receptor in mouse models recapitulates several features of the COX-2 inhibition, thus presenting a new avenue for anti-inflammatory therapy which could bypass some of the adverse side effects observed by the COX-2 inhibition therapy. We have recently reported a cinnamic amide class of EP2 antagonists with high potency, but these compounds exhibited a moderate selectivity against prostanoid receptor DP1. Moreover they possess acrylamide moiety in the structure, which may result in liver toxicity over longer period of use in a chronic disease model. Thus, we now developed a second generation compounds that devoid of the acrylamide functionality and possess high potency and improved (>1000-fold) selectivity to EP2 over other prostanoid receptors.
Introduction
Prostanoid receptor subtype EP2 has emerged as an important biological target, playing a protective as well as deleterious role in a variety of diseases [1, 2] . EP2 activation has been shown to be beneficial in ischemic stroke and glaucoma models [3, 4] . So far several agonists have been developed. A compound known as taprenepag isopropyl (PF-04217329) is undergoing phase-2 clinical evaluation for treating open-angle glaucoma and ocular hypertension [5, 6] . A significant body of evidence suggests that EP2 plays a pro-inflammatory role in central nervous system (CNS) disorders including Alzheimer's disease (AD) [7] , Parkinson's disease (PD) [8] , amyotrophic lateral sclerosis (ALS) [9] and status epilepticus (SE) [10] ; peripheral diseases such as rheumatoid arthritis (RA) [11] , inflammatory bowel disease [12] and cancer [13e15] . Thus a highly selective antagonist for this receptor could be useful to develop treatments for these diseases. So far, a majority of the conclusions about the deleterious roles of EP2 are drawn from studies of EP2 knockout models, which also displayed salt-sensitive hypertension and infertility [16, 17] . However, the data from pharmacological inhibition of this receptor are limited due to lack of selective EP2 antagonists until recently [18] . We recently reported a cinnamic amide class of EP2 antagonists which displayed high EP2 potency, but modest selectivity against a structurally close prostanoid receptor DP1 [19, 20] . We now report several second generation EP2 antagonists with high potency and selectivity.
EP2, a Gas-coupled receptor, is activated by the endogenous ligand PGE 2 , produced by the cyclooxygenase enzymes (COX-1, COX-2). Upon activation, EP2 stimulates adenylate cyclase resulting in elevation of cAMP, which initiates downstream signaling by protein kinase A (PKA) or exchange protein activated by cAMP (Epac) [1, 2, 21, 22] .
Results and discussion

First generation EP2 antagonists show low selectivity, solubility and ADME properties
We recently reported a high-throughput screening campaign that indentified cinnamic amide 1 (a.k.a. TG4-155) as an initial hit ( Fig. 1) . We initially synthesized about 27 analogs for structure activity relationship study, which resulted in several compounds that displayed a high EP2 potency [20] . However, they showed modest (~10-fold) selectivity against a close member of prostanoid receptor DP1. Moreover, several compounds displayed low aqueous solubility and metabolic stability in microsomal fractions of mouse and human liver. Despite the low stability in liver microsomes, a trifluoroindole derivative of cinnamic amide (2, a.k.a. TG6-10-1) displayed a plasma half-life of 1.7 h, and brain-to plasma ratio of 1.7, and is currently used as a lead compound for proof of concept studies [23] . Since then we synthesized 45 additional cinnamic amide derivatives to optimize the selectivity properties. From this, one compound TG8-21 displayed 181-fold selectivity to EP2 over DP1, but others showed <80-fold selectivity [19] .
A majority of the first generation derivatives possess an acrylamide unit ( Fig. 1) , a structural moiety that mimics a Michael acceptor functionality, which is known to be reactive towards biologically active nucleophiles, potentially leading to off-target effects. To test this hypothesis, we first treated 2 ( Fig. 1 ) with reduced glutathione (GSH) (3eq) in acetonitrile and water as a solvent system. However, this compound did not form any adduct with glutathione up until 72 h at ambient temperature. Furthermore, it was also not reacted by N-acetyl ethanethiol and a reactive morpholine, suggesting that the acrylamide in this class does not act like a Michael acceptor. In contrast, when we subjected the compound 2 to a reactive metabolite trapping test in human liver microsomes in the presence of NADPH and glutathione, it indicated the appearance of significant amount of glutathione adduct (þGSH-2H), in addition to other expected adducts (e.g. GSH þ Oe2H, GSH þ O). This result suggests that this class of compounds might form reactive metabolites by liver metabolism [24] . However, when we tested the compound 2 for off-target activity against 47 ancillary targets that include several receptors, kinases and CYP450 enzymes, it displayed weak activity only against serotonin 5HT2A receptor with IC 50 ¼ 7.5 mM [23] . We did not explore any further to determine whether the GSH adducts are stemming solely from acrylamide moiety, but we speculate that this moiety might be a primary cause for the formation of reactive metabolites by this chemical class. Thus, we designed a second generation of analogs in this class that is devoid of the acrylamide moiety for further SAR study and selectivity characterization.
Synthesis of second generation amide EP2 antagonists
Earlier structure activity relationship (SAR) study on 1 indicated that the acrylamide moiety is optimal, but not essential for EP2 bioactivity [19, 20] . The derivatives that are devoid of the acrylamide moiety, for example 3 ( Fig. 1 ) displayed EP2 Schild potency of 214 nM, a 90-fold smaller potency than 1 [19, 20] . Thus, we envisioned synthesizing a variety of a second generation analogs by shrinking the acrylamide to an 'amide' linker for further SAR study. We first synthesized amide derivatives 6a and 6b as shown in Scheme 1, starting from 2-(2-methyl-1H-indol-1-yl)ethan-1-amine (4a) and 3,4,5-trimethoxybenzoic acid (5a) and 3,4-dimethoxybenzoic acid (5b). The other substituted derivatives on the phenyl ring (6cez, 7aez, & 8aeu), isomeric 3-inodole derivatives (8xez, & 9aeg), and imidazole derivatives ((8vew) were synthesized analogous to 6a and 6b as illustrated by the general Scheme 1 (Table 1 for individual structures). (Table 1) . Interestingly, the 3,4,5-trimethoxyamide derivative 6a showed no EP2 activity, where as the 4,5-dimethoxyamide derivative 6b displayed strong EP2 potency (Schild K B ¼ 22 nM). Thus, we used 6b as a lead for the synthesis of other second generation amide derivatives. As shown in Table 1 , we first focused on derivatising the phenyl group with a variety of electron donating or withdrawing groups at various positions (ortho, meta and para). We describe the potency of these analogs in rank order in comparison to the 3,4-dimethoxyderivative 6b. For example, a compound with a single methoxy group at the para-position (6c) showed 3.4-fold less potency than dimethoxyderivative (6b), and a compound with paraethylamino group (6d) displayed nearly same activity as 6b. Interestingly, a para-dimethylaminoamide (6e), or para-diethylaminoamide (6f) exhibited about 2-fold or 8-fold improved EP2 potency respectively in comparison to 6b. Then we examined amides with lengthy alkyl groups such as two propyls (6g) and two butyls (6h), but they indicated that ethyl group is optimal for activity, because increasing the length of alkyls gradually decreases the potency (Table 1) . Nonetheless, the dipropylamino derivative displayed 2-fold higher potency than 6b. The unsubstituted amine derivative (6i) showed reduced potency by 9-fold, and the derivatives with hydroxyl group (6j) and guanidine group (6k) displayed loss of potency, suggesting this region may have been exposed into a hydrophobic region on the EP2 receptor. We then explored several electron withdrawing groups at the same paraposition of the phenyl ring. For example, an acetoxyderivative (6m) showed 6.7-fold less potency, an N-acetyl-derivative (8n) showed a 4-fold less and an N-benzoyl derivative (8o) showed 2-fold less in comparison to 6b. Moreover, an acetamide derivative (6p) showed about 6.7-fold less, and a dimethylacetamide (6q), diethylacetamide (6r) showed 58-fold and 35-fold less potency than 6b, respectively. Likewise, a cyano derivative (6s), and a tertbutylcarbaoxylate (6t) showed decreased potency by 6.2 and 4.4 efold, respectively. A carboxylic acid group (6u) also reduced EP2 potency (245 nM), suggesting electron donating groups enhance the EP2 potency whereas the withdrawing groups, at para-position of the phenyl ring, decrease potency (Table 1) .
We also synthesized and tested analogs with additional groups such as fluorine, trifluoromethyl, and methoxyl at the other positions (ortho (o), meta (m) and para (p)) of the phenyl to see any additional advantages to the potency, but mostly these groups either reduced the potency or brought no changes in comparison to the compounds without these groups. For example, a fluorine at mposition, next to alkylamino group, reduced the potency about 2-fold (cf. 7a vs. 6e; 7d vs. 6f), but a fluorine at the same position had no effect on p-cyano derivative (7h vs. 6s) and a p-methoxy derivative (7c vs. 6c), but moving the fluorine from m-position to oposition reduced the EP2 potency (7i vs. 7h). Likewise, a trifluoromethyl group next to p-ethylamino group had no impact on the EP2 potency (7f vs. 6d), but this group resulted in 113-fold reduced potency on p-diethylamino derivative (7e vs. 6f). Moreover, a methoxyl group at m-position also reduced the potency by 22-fold (cf. 7g vs. 6f), suggesting single substitution only at p-position of the phenyl is optimal for EP2 activity, and additional groups at other positions decrease the EP2 potency. We also tested compound with a sulfonamide at p-position on the phenyl ring, this group also reduced the potency by 21-fold (6v vs. 6b), and the same group at m-position resulted in loss of potency (6w vs. 6b), reinforcing the above assertion that substitution at p-position is optimal, but at m-position, it is detrimental to the EP2 potency (Table 1) .
We then explored derivatives in which the nitrogen heteroatom is connected to the phenyl ring with extra methylene group to determine whether p-amino (to the amide group) is essential for EP2 potency. For example, a p-methylamine derivative (6y) showed about 3-fold less potency than p-amino derivative (6i) and a compound with two methylene groups between phenyl and amine (6z) displayed 6-fold less potency than the p-amine derivative (6i), suggesting alkylamino groups directly attached to phenyl ring provide optimal EP2 potency than the ones that are away from the phenyl ring. Interestingly however, a tert-butylcarboxylate protected p-methylamino derivative (6x) showed 2.4-fold higher potency than the free p-amino derivative (6i) ( Table 1) .
We then synthesized and examined a variety of nitrogen heterocyclic rings at the p-position of the phenyl ring. Pyrrolidine (7j) and homopiperidine (7o) derivatives showed approximately equal potency to 6b. However, a piperidine derivative (7k) and a morpholine derivative (7p) both displayed about 2.3-fold higher EP2 potency than 6b (Table 1) . Furthermore, we also synthesized and tested analogs with a methyl group (7l) and an ethylester (7m) and carboxylic acid (7n), hydroxyl group (7w) on the piperidine ring. Interestingly, while the ethylester piperidine derivative (7m) showed 20-fold less, a carboxylic acid displayed 4-fold less activity to 6b, and a hydroxylpiperidine derivatives displayed nearly equal EP2 potency as 6b (Table 1) , indicating hydrophilic groups on the piperidine ring will help to maintain the EP2 potency. Likewise, a methylpiperazine (7q), or a methylhomopiperizine ring (7v) at pposition of the phenyl ring also resulted in 2.8-fold or 6.6-fold loss of potency, in comparison to 6b. We then explored SAR by moving these heterocyclic rings from p-position to m-position. But this strategy resulted in less active compounds in comparison to psubstituted derivatives (cf. 7s vs. 7p; 7r vs. 7q). Likewise, incorporation of fluorine atom at m-position on the phenyl ring (next to the heterocyclic rings) showed a trend towards increasing the potency in one case (cf. 7u vs. 7q), but decreased the potency by 2-fold in other (cf. 7t vs. 7p), reinforcing the suggestion (vide infra) that a single group at p-position provides optimal higher EP2 potency. We further explored other heterocyclics at the p-position of the phenyl ring (7xez), and few benzofused heterocyclics (8a, 8e and 8f) for SAR study. The 1-tetrazoles 7x and 7y displayed 1.5e2-fold less potency, but the 5-tetrazole (7z) and the benzofusedimidazole (8a) displayed equal potency to 6b, whereas the benzofused-triazole (8e) and benzofused-quinazoline (8f) both displayed 4-fold reduced potency in comparison to 6b. Interestingly, a cyclohexane ring at p-position (8b) showed 5.5-fold less potency in comparison to 6b, suggesting nitrogen in the ring helps maintain the potency at <100 nM, but a heteroatom is not absolutely essential for full bioactivity. Again a strategy to extend these heterocyclic rings with an extra methylene group or oxygen atom resulted in loss of potency (see 8iek), reinforcing the notion that direct nitrogen attachment to the phenyl ring will improve potency ( Table 1) .
We also envisioned synthesizing compounds with a pyrimidine ring replacing the phenyl ring, then exploring substitutions on this ring. As shown in Table 1 , a 2-aminopyrimidine-amide (8l) displayed loss of potency, in comparison to an equivalent 6i which displayed EP2 potency of 210 nM. However, a 2-ethylamino derivative (8n) or, 2-morpholino derivative (8o) showed EP2 potency of 58 and 76.5 nM, respectively. These potencies are 4e8-fold less than their equivalents 6d, 7p. In contrast, a 2-phenylamino derivative exhibited a higher EP2 potency (Schild K B ¼ 1.6 nM). Moreover, we also examined compounds in which the phenyl ring is replaced by a nicotinamide ring (8p), and a pyrimidine substituted cyclohexane ring (8q), but both these derivatives displayed about 20-fold less potency in comparison to 6b, suggesting phenyl or pyrimidine rings are optimal for high EP2 potency. Furthermore, we synthesized and tested additional heterocycles such as imidazole (9h), 4-hydroxyquinoline (9i), and pyrrolidine (9j), replacing the phenyl ring. However, 2-imidazole derivative 9h, 2-quinoline compound 9i showed weak EP2 potency (K B ¼ 128 nM, 174 nM respectively), and the pyrrolidine derivative (9j) displayed loss of potency. These results suggest further modifications on this phenyl region may yield compounds with enhanced bioactivity.
Having identified several compounds with EP2 potency <50 nM with modifications on the right side phenyl ring, we explored the left side indole ring to determine whether any enhancement to the potency is possible. Blocking the ortho-, and para-positions to the indole ring nitrogen could potentially limit metabolic oxidation of the scaffold. Thus we have synthesized two compounds (8r and 8s) with fluorine at 5th position of the indole ring (Table 1) . Interestingly, these two compounds displayed similar potencies in comparison to the unsubstituted derivatives (8r vs. 7p; 8s vs. 7u), but we have not yet explored the o-position to the indole nitrogen due to lack of available starting materials for synthesis. From our earlier SAR on the first generation analogs, we learned that only limited modifications (e.g. CF 3 ) are allowable at 2nd position of the indole ring with about 10-fold loss of potency (cf. 1 vs. 2) [20] . Thus, we only synthesized a few analogs with a trifluoromethyl group at 2nd position. As shown by two examples, 8t and 8u (Table 1) , the trifluoromethyl group at 2nd position resulted in 12e54-fold less EP2 potency in comparison to a methyl group at the same position (8t vs. 6f; 8u vs. 7p). We also synthesized analogs with imidazole ring in place of indole ring with premise that an extra nitrogen in the imidazole ring offers additional drug like features, including enhanced solubility and metabolic stability by blocking the 3rd position, where this position seems to liable in the case of indoles [25] . However, an imidazole derivative (8v) showed a 70-fold less potency than its indole equivalent compound (6f). One point is noteworthy here. In the earlier study, we observed that a methyl group at 2nd position of the indole ring accelerates metabolism in liver fractions compared with a trifluoromethyl group [20] . Thus, we synthesized analogs without a methyl group at 2nd position of the indole (6l), and imidazole ring (8w). However, the indole derivative without methyl group (6l) was found to be 23-fold less potent than its methyl equivalent (6f), and the imidazole derivative without methyl group (8w) displayed complete loss of EP2 potency, reinforcing the observation that methyl is very important for high EP2 bioactivity (Table 1) .
We then examined isomeric 3-indole derivatives (8xe8z, 9ae9g) for SAR study. As shown in Table 1 , the 3-indole isomeric derivatives showed nearly equal potency to their 1-indole equivalent compounds (cf. 8x vs.6n; 8y vs. 6r; 8z vs. 6e; 9a vs. 6f; 9b vs. 7k; 9c vs. 7p; 9d vs. 7t; 9e vs. 7q), suggesting both 1-indole and 3-indole derivatives are, in general, are potent antagonist of EP2 receptor and useful for further development of EP2 drugs.
Finally, we explored the linker region for SAR study. Extension of the chain from two carbons to three carbons, as illustrated by the indolepropane amide (9k), constraining the linker as in derivatives 9l and 9m (Fig. 2 ) resulted in loss of potency in comparison to their shorter equivalents (6f and 7p). Moreover, we also synthesized an ester analog (9n) to determine whether the amide bond is necessary for EP2 potency. This analog resulted in loss of potency, indicating that the amide is crucial for the EP2 bioactivity.
Overall, the SAR study indicates a dialkylaminogroup or nitrogen heterocycles at p-position, a methyl group at 2nd position of indole ring, and an ethylamine linker are optimal for high EP2 potency. The compounds 6f, 7p, 7z, 8z, 9a and 7k, 7p display high EP2 potency, with Schild K B approximately 10 nM. However, several other compounds (Table 1) displayed EP2 potency below 100 nM, and a variety of heterocycles retains a modest EP2 potency, suggesting these scaffolds could be further refined into highly potent antagonists for the EP2 receptor.
Characterization of selectivity against other prostanoid receptors
The EP2 receptor is a member of the prostanoid receptor family and shares 20e30% structural homology with EP1, EP3 and EP4, all of these are activated by a common agonist PGE 2 . However, EP2 exhibits the highest amino acid homology to DP1 (44%) and IP (40%) receptors, which are activated by PGD 2 and PGI 2 respectively [26e28]. Furthermore, studies indicate that DP1 has similar physiological functions as EP2 [27] , whereas the activation of the IP receptor is shown to be important for cardioprotection [29, 30] . EP2, EP4, DP1 and IP are all Gas-coupled transmembrane receptors [27] . Thus we examined the selectivity of the novel EP2 antagonists mainly over EP4, DP1 and IP. We selected and tested several highly potent second generation amide EP2 antagonists that showed EP2 K B 50 nM. Interestingly, these amide derivatives showed much improved selectivity in comparison to the first generations derivatives. For example, 6f displayed >1200-fold selectivity against DP1 receptor (Table 2) , compound 6e displayed 655-fold, and 7j and 7p showed 516-fold and 533-fold selectivity over DP1 respectively. Moreover, compounds 6g, 7k, and 10z displayed over 275-fold selectivity against DP1.
We then examined several of these compounds against EP4 and IP receptors at single concentration of 10 mM. The extrapolated Schild K B s for these receptors are shown Table 2 . A vast majority of these derivatives displayed >1000-fold selectivity over EP4, but a few derivatives such as 7t, and 7z displayed only~600-fold selectivity, and one other compound 7u displayed a moderate (100-fold) selectivity. Several of these compounds also displayed very good selectivity against the IP receptor. For example 6f and 9c displayed 3000-fold selectivity; 7z, and 8a exhibited >1000-fold selectivity; 7j, 7k, and 7w exhibited selectivity in the range of 300e600-fold. Furthermore, we tested these derivatives to determine whether they reduced viability of the parent C6-glioma cells, but a majority of these derivatives showed an effect only at high micromolar concentrations (>300 mM) with in vitro therapeutic indexes >10,000, except two compounds 7w and 8a, both of which showed an effect on cell viability at >100 mM. Nonetheless, in vitro therapeutic indexes >6000-fold indicating that the bioactivity by this class of amide compounds is not driven by cell viability (Table 2) .
Second generation amide derivatives show competitive mechanism of inhibition
We have previously demonstrated that first generation acrylamide analogs 1 and 2 exhibit a competitive EP2 antagonism of EP2 [20, 23] . To confirm whether the second generation amides derivatives also display competitive antagonism of EP2, we selected 3 potent compounds 6f, 7p, 9a and subjected them to a concentrationeresponse test on EC 50 of PGE 2 on EP2 receptors overexpressed in C6-glioma cells. A linear regression of log (dr-1) on log X B with slope of unity characterizes a competitive antagonism. Schild K B values are derived by the equation log (dr À 1) ¼ log X B À log K B , where dr ¼ dose ratio, i.e. the fold shift in EC 50 ; X B is [antagonist] , and K B is the equilibrium dissociation constant for the antagonistereceptor complex. K B value indicates the antagonist concentration required for a twofold rightward shift in the PGE 2 doseeresponse curve. Thus, a lower K B value indicates a higher inhibitory potency. All the selected members of the second generation compounds induced a concentration-dependent, parallel, rightward shift in the PGE 2 concentrationeresponse curve (Fig. 3AeC) . The Schild regression analyses demonstrated that these compounds have a competitive mechanism of antagonism of EP2 (Fig. 3D) 
Determination of liver microsomal stability and pharmacokinetics of the second generation amide antagonists
Fifteen potent and selective EP2 antagonists were subjected to a stability test in human and mouse liver microsomal fractions. As shown in Supporting Table 1 , several compounds showed moderate to good stability in human microsomes, but a few of them (6e, 7p, 8z and 9c) were metabolized completely in mouse liver microsomes in 60 min (<1% remaining). However, compounds 7j, 7k, 7x, & 8m displayed >7% remaining at 60 min in mouse liver fractions, thus are potential candidates to study further. The other noteworthy examples are a 5-tetrazole derivative 7z and a carboxypiperidine derivative 7n, both of which displayed high stability in mouse and human liver microsomes with greater than 50% remaining at 60 min. These two derivatives also displayed high aqueous solubility by nephelometry [31] , when measured in PBS buffer (pH 7.4) with 1% DMSO (Supporting Table 1 ).
Although the selectivity of 7z is moderate against DP1 (30-fold), we selected it for in vivo pharmacokinetic study on the basis of its high stability in both microsomal fractions and its aqueous solubility. As shown in Supporting Table 2 , it displayed about 12-fold higher peak concentrations in plasma by intraperitoneal (ip) route of administration, in comparison to an oral route (po). It 
Conclusions
We developed a novel compound series that are devoid of highly vulnerable acrylamide functionality, but still possess high EP2 potency and high selectivity against DP1, EP4 and IP receptors. Further studies to characterize drug-like properties of these selected EP2 antagonists are currently undergoing, but compounds 6e, 6f, 7j, 7p, 8a, and 9a display a potent and selective antagonism of the EP2, and may be useful as tools for in vitro studies.
Experimental
Chemistry
Proton NMR spectra was recorded on a Varian Inova-400 (400 MHz). Thin layer chromatography was performed on precoated, aluminum-backed plates (silica gel 60 F 254 , 0.25 mm thickness) from EM Science and was visualized by UV lamp.
Column chromatography was performed with silica gel cartridges on Teledyne-ISCO machine. Agilent LCeMS was used to measure purity of the products. Elemental analyses were performed by Atlantic Microlab Inc. (Norcross, GA).
N-(2-(2-methyl-1H-indol-1-yl)ethyl)-4-(piperidin-1-yl) benzamide (7k) (TG7-152) (typical procedure)
A solution of 2-(2-methyl-1H-indol-1-yl)ethanamine (4a) (65 mg, 0.373 mmol) and 4-(piperidin-1-yl)benzoic acid (5) (76 mg, 1 eq.), and dimethylaminopyridine (catalytic,~5 mg) in dichloromethane (6 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide.hydrochloride (EDCI) (92 mg, 1.3 eq.) at room temperature. The resulting reaction mixture was stirred for 6 h. At the conclusion of the reaction (TLC), water (15 mL) was added to quench the reaction. The product was extracted with ethyl acetate (20 mL Â 3). Organics were washed with dilute HCl (10 mL), saturated NaHCO 3 solution (10 mL), water (10 mL) and brine solution (10 mL) and dried over Na 2 SO 4 and concentrated. The resulting crude product was subjected to silica gel chromatography eluting with 0e40% ethyl acetate in hexane to furnish 7k (TG7-152) (100 mg, 74% yield). 1 Table 1 
4-(Ethylamino)-N-(2-(2-methyl-1H-indol-1-yl)ethyl) benzamide (6d) (TG7-237)
